Cargando…
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
Autores principales: | Molina, J.M., Delaugerre, C., Le Goff, J., Mela-Lima, B., Ponscarme, D., Goldwirt, L., de Castro, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195369/ https://www.ncbi.nlm.nih.gov/pubmed/32240719 http://dx.doi.org/10.1016/j.medmal.2020.03.006 |
Ejemplares similares
-
Complete Clearance of Cutaneous Warts with Hydroxychloroquine: Antiviral Action?
por: Bhushan, Premanshu, et al.
Publicado: (2014) -
Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann
por: Gautret, Philippe, et al.
Publicado: (2021) -
No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on “Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France”
por: Lebeaux, David, et al.
Publicado: (2020) -
Hydroxychloroquine- and azithromycin-related heart disorders
Publicado: (2020) -
Hydroxychloroquine + azithromycin treatment in elderly patients
por: Gautret, Philippe, et al.
Publicado: (2021)